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Autoimmune limbic encephalitis 
Editor – We read with interest the recent
article by Derry et al (Clin Med October
2011 pp 479–82) concerning limbic
encephalitis (LE). There are important
additional issues leading on from this suc-
cinct article that may be useful to the gen-
eral physician when considering a LE
diagnosis.
As reflected in the article, the diagnosis
of autoimmune encephalitis (AE) and,
more specifically, LE is a difficult one with
no causative agent identified in up to two-
thirds of encephalitic patients referred to
specialist centres.1
As mentioned in the article, recent work
has indicated potassium channels are not the
antigenic target in LE and it is in fact Anti-
LGI1 (Leucine-rich glioma inactivate 1).2,3 In
addition, other studies suggest that another
auto-antigen ‘CASPR2 - contactin-associated
protein-like 2’ (expressed in hippocampal
neurons) is associated with illnesses previ-
ously attributed to anti-VGKC antibodies
such as drug-refractory epilepsy, encephalitis,
peripheral nerve dysfunction, or a combina-
tion of both: Morvan syndrome or neuromy-
otonia.4–7 Therefore, the term ‘anti-VGKC’
encephalitis is no longer in routine use.
The authors rightly illustrate the cardinal
symptoms of LE as being severe short-term
memory impairment with psychiatric
symptoms such as personality change,
depression, anxiety, hallucinations, confu-
sion, and complex partial (often temporal)
and generalised seizures.8,9 It must be
recalled that auto-antibodies may take
some weeks to process and often LE treat-
ment will have to be initiated prior to
definitive diagnosis. With this in mind,
there are other clinical features that may
assist in pointing the clinician towards the
diagnosis of LE. Features classically associ-
ated with anti-LGI1 encephalitis include
faciobrachial tonic seizures7 and, in 40% of
patients, myoclonus.2 With regards to ini-
tial blood tests, hyponatraemia is a
common finding in patients with 
anti-LGI1 encephalitis being found in
patients both with and without underlying
malignancy, indicating that it is not 
purely a paraneoplastic phenomenon.10
Autonomic instability is also described. 
Once LE has been identified, it is essen-
tial to exclude paraneoplastic aetiology
such as anti-Hu or anti-Ma2 associated LE
as tumour treatment and, if possible,
removal is associated with better outcomes
than immunomodulatory therapy alone.3
It is important to note that the encephalitic
presentation will precede the identification
of the neoplasm in up to three quarters of
patients.9,11,12
Thankfully, as the article points out,
non-paraneoplastic LE is associated with
good outcomes if recognised early and
treated aggressively. However, the clinician
must be alert to the fact that residual neu-
rological deficits may be subtle, difficult to
elicit and, in some cases, sufficient to pre-
clude the patient’s return to work.
It is clear that the earlier AE or LE is
diagnosed and therapy started, the better
the outcome. We recently published an AE
review containing a clinical algorithm for
work-up, diagnosis, and treatment of
autoimmune encephalitis13 that – in con-
junction with important articles such as
Derry et al’s – we hope will assist the neu-
rologist and generalist alike in early AE
diagnosis and treatment.
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The changing landscape of
anticoagulation and atrial
fibrillation 
Editor – We read with great interest the
article by Breen and Hunt which pre-
sented an overview of the new oral anti-
coagulants (Clin Med October 2011 pp
497–9). We wish to highlight three new
studies published since their review was
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